At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MGTX Meiragtx Holdings Plc
Market Closed 02-21 16:00:00 EST
7.30
+0.47
+6.88%
盘后7.60
+0.30+4.11%
18:48 EST
High7.80
Low6.87
Vol954.29K
Open7.35
D1 Closing6.83
Amplitude13.55%
Mkt Cap570.52M
Tradable Cap224.08M
Total Shares78.15M
T/O7.05M
T/O Rate3.11%
Tradable Shares30.70M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
data is loading...
MeiraGTx Announces The Lancet Publication of Data Demonstrating the Efficacy of rAAV8.hRKp.AIPL1 for the Treatment of Leber Congenital Amaurosis 4 (LCA4) Retinal Dystrophy
MeiraGTx Announces the Lancet Publication of Data Demonstrating the Efficacy of Raav8.hrkp.aipl1 for the Treatment of Leber Congenital Amaurosis 4 (Lca4) Retinal Dystrophy
MeiraGTx Receives Rare Pediatric Disease Designation From FDA for Aav8-Rk-Retgc for the Treatment of Patients With Leber Congenital Amaurosis Due to Gucy2d Mutations
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Aav2-Haqp1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.